Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model

[1] Antolino-Lobo I(2010)Differential roles of phase I and phase II enzymes in 3, 4-methylendioxymethamphetamine-induced cytotoxicity Drug Metab Dispos 38 1105-1112

[2] Meulenbelt J(2003)Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine Drug Metab Dispos 31 289-293

[3] Nijmeijer SM(2004)Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine Drug Metab Dispos 32 1213-1217

[4] Scherpenisse P(2007)Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment Xenobiotica 37 1225-1256

[5] van den Berg M(1998)Mirtazapine, an antidepressant Am J Health Syst Pharm 55 44-49

[6] van Duursen MB(1997)A risk-benefit assessment of mirtazapine in the treatment of depression Drug Saf 17 251-264

[7] Bertelsen KM(2001)A review of the pharmacological and clinical profile of mirtazapine CNS Drug Rev 7 249-264

[8] Venkatakrishnan K(2000)Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4 Drug Metab Dispos 28 1168-1175

[9] Von Moltke LL(2000)Clinical pharmacokinetics of mirtazapine Clin Pharmacokinet 38 461-474

[10] Obach RS(2002)Synthesis and capillary electrophoretic analysis of enantiomerically enriched reference standards of MDMA and its main metabolites Bioorg Med Chem 10 1085-1092

[1] Antolino-Lobo I(2010)Differential roles of phase I and phase II enzymes in 3, 4-methylendioxymethamphetamine-induced cytotoxicity Drug Metab Dispos 38 1105-1112

[2] Meulenbelt J(2003)Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine Drug Metab Dispos 31 289-293

[3] Nijmeijer SM(2004)Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine Drug Metab Dispos 32 1213-1217

[4] Scherpenisse P(2007)Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment Xenobiotica 37 1225-1256

[5] van den Berg M(1998)Mirtazapine, an antidepressant Am J Health Syst Pharm 55 44-49

[6] van Duursen MB(1997)A risk-benefit assessment of mirtazapine in the treatment of depression Drug Saf 17 251-264

[7] Bertelsen KM(2001)A review of the pharmacological and clinical profile of mirtazapine CNS Drug Rev 7 249-264

[8] Venkatakrishnan K(2000)Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4 Drug Metab Dispos 28 1168-1175

[9] Von Moltke LL(2000)Clinical pharmacokinetics of mirtazapine Clin Pharmacokinet 38 461-474

[10] Obach RS(2002)Synthesis and capillary electrophoretic analysis of enantiomerically enriched reference standards of MDMA and its main metabolites Bioorg Med Chem 10 1085-1092